ArticleFrontiers in pediatrics2025
Analysis of adverse reactions and cost-driving factors during the induction phase of pediatric acute lymphoblastic leukemia.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Exercise intervention for children with acute leukemia: a best evidence summary.Frontiers in pediatrics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and incurs high medical costs due to the complexity and duration of treatment. This study aimed to analyze the incidence of adverse reactions during the induction phase of ALL treatment and identify key factors influencing hospitalization costs. Methods: A retrospective analysis was conducted on 292 newly diagnosed cases of ALL in children who received induction therapy at Hebei Children's Hospital (2020-2024) under the CCLG-ALL-2018 protocol. Demographic, clinical, laboratory, and hospitalization cost data were collected. Adverse reactions were graded using the Common Terminology Criteria for Adverse Events version 5.0. Hospitalization costs were analyzed using the structural variation method and grey relational analysis. Multivariate linear regression was performed to identify cost-related factors. Results: The median patient age was 4.9 years (male:female = 6:4). Most cases were B-cell ALL (88.36%), and 69.52% were classified as intermediate risk. Adverse reaction rates were relatively low, including allergic reactions (2.74%), pancreatic toxicity (3.77%), and hepatotoxicity (13.36%). Infections were common, with sepsis occurring in 49.32% and pneumonia in 32.19% of cases. The mean hospitalization costs during the induction phase decreased from 77,690 RMB in 2020 to 56,263 RMB in 2024. Diagnostic fees (37.55%) and medication (30.52%) represented the largest cost components. Hospitalization days, intravenous antifungal medication, tumor lysis syndrome, blood product usage, severe pneumonia infection, surgery performed and discharge yearwere determined to be independent predictors of increased costs. Conclusions: Adverse reactions and complications markedly burden induction treatment. Optimizing protocols, improving monitoring, and implementing cost-control measures can enhance outcomes and reduce costs. Larger sample sizes and socioeconomic variables should be included in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.